BACKGROUND: Norovirus (NoV) is the leading cause of epidemic gastroenteritis worldwide. The lack of a cell culture has significantly hampered the development of effective therapies against human NoV. Clinically approved nucleoside and non-nucleoside analogues have been used successfully against RNA viruses. METHODS: In this study, we evaluated the efficacy of four nucleoside analogues (2'-C-MeC, 2'-F-2'-C-MeC, β-D-N(4)-hydroxycytidine [NHC] and lamivudine) on Norwalk virus (NV) RNA levels and protein expression in NV replicon-harbouring cells (HG23 cells), and their efficacy in blocking murine norovirus (MNV) replication in RAW 264.7 cells. RESULTS: 2'-C-MeC and 2'-F-2'-C-MeC reduced MNV RNA levels and infectivity in RAW 264.7 cells in a concentration- and time-dependent manner. The median effective concentrations (EC(50)) of 2'-C-MeC and 2'-F-2'-C-MeC were 6.9 μM and 12.7 μM, respectively. 2'-C-MeC, 2'-F-2'-C-MeC and NHC reduced NV RNA levels and protein expression in HG23 cells. For the NV replicon, the EC(50) of 2'-C-MeC (1.3 μM) was comparable to the antiviral activity of NHC (1.5 μM) and twofold more potent than 2'-F-2'-C-MeC (3.2 μM). The combination of 2'-C-MeC/ribavirin resulted in modest synergistic activity, whereas NHC/ribavirin was antagonistic for NV replication in HG23 cells. CONCLUSIONS: The antiviral activity of 2'-C-MeC against strains of two different NoV genogroups and the low EC(50) suggest that this nucleoside analogue may be effective against the more prevalent GII NoVs. In the absence of a vaccine, antiviral agents could be an effective intervention to control the spread of human NoV in populations at a high risk for NoV disease.
BACKGROUND: Norovirus (NoV) is the leading cause of epidemic gastroenteritis worldwide. The lack of a cell culture has significantly hampered the development of effective therapies against human NoV. Clinically approved nucleoside and non-nucleoside analogues have been used successfully against RNA viruses. METHODS: In this study, we evaluated the efficacy of four nucleoside analogues (2'-C-MeC, 2'-F-2'-C-MeC, β-D-N(4)-hydroxycytidine [NHC] and lamivudine) on Norwalk virus (NV) RNA levels and protein expression in NV replicon-harbouring cells (HG23 cells), and their efficacy in blocking murine norovirus (MNV) replication in RAW 264.7 cells. RESULTS:2'-C-MeC and 2'-F-2'-C-MeC reduced MNV RNA levels and infectivity in RAW 264.7 cells in a concentration- and time-dependent manner. The median effective concentrations (EC(50)) of 2'-C-MeC and 2'-F-2'-C-MeC were 6.9 μM and 12.7 μM, respectively. 2'-C-MeC, 2'-F-2'-C-MeC and NHC reduced NV RNA levels and protein expression in HG23 cells. For the NV replicon, the EC(50) of 2'-C-MeC (1.3 μM) was comparable to the antiviral activity of NHC (1.5 μM) and twofold more potent than 2'-F-2'-C-MeC (3.2 μM). The combination of 2'-C-MeC/ribavirin resulted in modest synergistic activity, whereas NHC/ribavirin was antagonistic for NV replication in HG23 cells. CONCLUSIONS: The antiviral activity of 2'-C-MeC against strains of two different NoV genogroups and the low EC(50) suggest that this nucleoside analogue may be effective against the more prevalent GII NoVs. In the absence of a vaccine, antiviral agents could be an effective intervention to control the spread of human NoV in populations at a high risk for NoV disease.
Authors: Rowena A Bull; Jennifer Hyde; Jason M Mackenzie; Grant S Hansman; Tomoichiro Oka; Naokazu Takeda; Peter A White Journal: Virus Genes Date: 2010-10-20 Impact factor: 2.332
Authors: Claire Pierra; Agnès Amador; Samira Benzaria; Erika Cretton-Scott; Marc D'Amours; John Mao; Steven Mathieu; Adel Moussa; Edward G Bridges; David N Standring; Jean-Pierre Sommadossi; Richard Storer; Gilles Gosselin Journal: J Med Chem Date: 2006-11-02 Impact factor: 7.446
Authors: Jack T Nguyen; Justin D Hoopes; Donald F Smee; Mark N Prichard; Elizabeth M Driebe; David M Engelthaler; Minh H Le; Paul S Keim; R Paul Spence; Gregory T Went Journal: Antimicrob Agents Chemother Date: 2009-07-20 Impact factor: 5.191
Authors: Dmitry F Zamyatkin; Francisco Parra; José M Martín Alonso; Daniel A Harki; Blake R Peterson; Pawel Grochulski; Kenneth K-S Ng Journal: J Biol Chem Date: 2008-01-09 Impact factor: 5.157
Authors: Elaine Scallan; Robert M Hoekstra; Frederick J Angulo; Robert V Tauxe; Marc-Alain Widdowson; Sharon L Roy; Jeffery L Jones; Patricia M Griffin Journal: Emerg Infect Dis Date: 2011-01 Impact factor: 6.883
Authors: Martin C W Chan; Joseph J Y Sung; Rebecca K Y Lam; Paul K S Chan; Nelson L S Lee; Raymond W M Lai; Wai K Leung Journal: Emerg Infect Dis Date: 2006-08 Impact factor: 6.883
Authors: Auda A Eltahla; Kun Lee Lim; John-Sebastian Eden; Andrew G Kelly; Jason M Mackenzie; Peter A White Journal: Antimicrob Agents Chemother Date: 2014-03-17 Impact factor: 5.191
Authors: Nadya Urakova; Valeriya Kuznetsova; David K Crossman; Arpine Sokratian; David B Guthrie; Alexander A Kolykhalov; Mark A Lockwood; Michael G Natchus; Michael R Crowley; George R Painter; Elena I Frolova; Ilya Frolov Journal: J Virol Date: 2018-01-17 Impact factor: 5.103
Authors: Everardo Vega; Eric Donaldson; Jeremy Huynh; Leslie Barclay; Ben Lopman; Ralph Baric; Luke F Chen; Jan Vinjé Journal: J Virol Date: 2014-10-01 Impact factor: 5.103
Authors: Holly Freedman; Juthika Kundu; Egor Petrovitch Tchesnokov; John Lok Man Law; James A Nieman; Raymond F Schinazi; D Lorne Tyrrell; Matthias Gotte; Michael Houghton Journal: J Chem Inf Model Date: 2020-12-01 Impact factor: 4.956
Authors: Anushka C Galasiti Kankanamalage; Pathum M Weerawarna; Yunjeong Kim; Kyeong-Ok Chang; William C Groutas Journal: Expert Opin Ther Pat Date: 2016 Impact factor: 6.674
Authors: Mike Flint; Laura K McMullan; Kimberly A Dodd; Brian H Bird; Marina L Khristova; Stuart T Nichol; Christina F Spiropoulou Journal: Antimicrob Agents Chemother Date: 2014-03-24 Impact factor: 5.191